{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:09:34Z","timestamp":1761883774170,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.reumae.2020.08.009","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T07:23:31Z","timestamp":1643095411000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"18","author":[{"given":"Jes\u00fas","family":"Tornero-Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Alperi-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Castellv\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"de Agust\u00edn-de Oro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Casamira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Calvo-Al\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2020.08.009_bib0290","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.reuma.2016.12.001","article-title":"Recommendations for the use of parenteral methotrexate in rheumatic diseases","volume":"14","author":"Tornero Molina","year":"2018","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.08.009_bib0300","first-page":"279","article-title":"2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis","volume":"11","author":"Sanmarti","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.08.009_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0310","unstructured":"Medicine. CCfEB 2011; 2019. Accessed at University of Oxford at http:\/\/www.cebm.net\/index.aspx?o=1025 (11\/04\/13)."},{"key":"10.1016\/j.reumae.2020.08.009_bib0315","first-page":"409","article-title":"Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis","volume":"21","author":"Buckley","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.reumae.2020.08.009_bib0320","article-title":"Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: a systematic review and meta-analysis of randomised trials","author":"Tarp","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.08.009_bib0325","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1097\/MJT.0000000000000645","article-title":"Abatacept monotherapy versus abatacept plus methotrexate for treatment-refractory rheumatoid arthritis","volume":"26","author":"Pascart","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.reumae.2020.08.009_bib0330","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12891-015-0636-9","article-title":"Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study","volume":"16","author":"Nusslein","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.reumae.2020.08.009_bib0335","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2011-200003","article-title":"Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration","volume":"71","author":"Chatzidionysiou","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0340","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s12325-018-0757-2","article-title":"Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review","volume":"35","author":"Emery","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.reumae.2020.08.009_bib0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","article-title":"Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study","volume":"74","author":"Huizinga","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0350","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","article-title":"Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0355","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0360","article-title":"Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis","author":"Tornero Molina","year":"2018","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.08.009_bib0365","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/annrheumdis-2016-210711","article-title":"Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Chatzidionysiou","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0370","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/annrheumdis-2016-209383","article-title":"Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review","volume":"75","author":"Duran","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0375","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.08.009_bib0380","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.151009","article-title":"Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial","volume":"43","author":"Kaeley","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0385","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0390","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2020.08.009_bib0395","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.08.009_bib0400","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.08.009_bib0405","article-title":"Real-world experience with tofacitinib for treatment of rheumatoid arthritis","author":"Caporali","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0410","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.08.009_bib0415","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/14397595.2018.1553489","article-title":"Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post hoc analysis of clinical trial data","volume":"29","author":"Takeuchi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0420","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.08.009_bib0425","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2020.08.009_bib0430","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","article-title":"Sustained remission with etanercept tapering in early rheumatoid arthritis","volume":"371","author":"Emery","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2020.08.009_bib0435","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study","volume":"78","author":"van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0440","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/kex358","article-title":"Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial","volume":"57","author":"Edwards","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2020.08.009_bib0445","first-page":"437","article-title":"Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study","volume":"37","author":"Pablos","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0450","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","article-title":"Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial","volume":"73","author":"Mariette","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0455","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/annrheumdis-2014-206149","article-title":"Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis","volume":"74","author":"Westhovens","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0460","doi-asserted-by":"crossref","first-page":"e00452","DOI":"10.1016\/j.heliyon.2017.e00452","article-title":"REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients","volume":"3","author":"Gonzalez-Alvaro","year":"2017","journal-title":"Heliyon"},{"key":"10.1016\/j.reumae.2020.08.009_bib0465","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1488-5","article-title":"Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting","volume":"20","author":"Alten","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2020.08.009_bib0475","doi-asserted-by":"crossref","first-page":"e0123392","DOI":"10.1371\/journal.pone.0123392","article-title":"Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis","volume":"10","author":"Narvaez","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.reumae.2020.08.009_bib0480","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/03009742.2016.1234641","article-title":"Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland","volume":"46","author":"Aaltonen","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0485","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/03009742.2016.1141979","article-title":"Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice","volume":"45","author":"Leon","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0490","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","article-title":"Long-term persistence with rituximab in patients with rheumatoid arthritis","volume":"57","author":"Oldroyd","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reumae.2020.08.009_bib0495","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10067-016-3485-5","article-title":"Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis","volume":"36","author":"Kihara","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0500","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","article-title":"Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis","volume":"173","author":"Maneiro","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.reumae.2020.08.009_bib0505","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.reumae.2020.08.009_bib0510","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.reumae.2020.08.009_bib0515","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00296-018-4022-4","article-title":"Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review","volume":"38","author":"Martin-Lopez","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2020.08.009_bib0520","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2020.08.009_bib0525","article-title":"Practical aspects of biological throughput levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis","author":"Rosas","year":"2018","journal-title":"Reumatol Clin"},{"issue":"Suppl. S10","key":"10.1016\/j.reumae.2020.08.009_bib0530","first-page":"2368","article-title":"Underuse of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the United States (US): results of a claims analysis","volume":"67","author":"O\u2019Dell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2020.08.009_bib0535","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2015.02.009","article-title":"Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort","volume":"45","author":"Muller","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.08.009_bib0540","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/rmdopen-2016-000371","article-title":"Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2020.08.009_bib0545","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/rmdopen-2017-000491","article-title":"Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2020.08.009_bib0550","doi-asserted-by":"crossref","first-page":"e000352","DOI":"10.1136\/rmdopen-2016-000352","article-title":"No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis","volume":"3","author":"Baradat","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2020.08.009_bib0555","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2020.08.009_bib0560","first-page":"284","article-title":"Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients","volume":"7","author":"Gomez Reino","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.08.009_bib0565","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.reuma.2014.02.012","article-title":"Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes","volume":"11","author":"Tornero Molina","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2020.08.009_bib0570","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574322000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574322000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:59:46Z","timestamp":1761879586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574322000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2173574322000120"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2020.08.009","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}